Perspective Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online.

See all article types »

Pharmacogenetics in the Management of Coumarin Anticoagulant Therapy: The Way Forward or an Expensive Diversion?

  • Mike Greaves
  • Published: October 25, 2005
  • DOI: 10.1371/journal.pmed.0020342

About the Author

Competing Interests

I have been a paid expert advisor, on an ad hoc basis, to AstraZeneca (London, United Kingdom), a company developing thrombin inhibitors. I have no financial interest in this company's success (I have no shares in the company, nor have I received grants or awards from the company).